Utility of blood procalcitonin concentration in the management of cancer patients with infections

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 469-475

  Durnaś, Bonita ^a,b   Wątek, Marzena ^a   Wollny, Tomasz ^a   Niemirowicz, Katarzyna ^c   Marzec, Michał ^d   Bucki, Robert ^b,c   Góźdź, Stanisław ^a  

^a Center Holy Cross Regional Hospital   (Poland)

^b JAN KOCHANOWSKI UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Infection; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

BACTERIAL INFECTION; BLOODSTREAM INFECTION; CANCER PATIENT; CANCER STAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEVER; HUMAN; INFECTION; INFLAMMATION; KIDNEY DYSFUNCTION; MYCOSIS; PNEUMONIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SEPSIS;

EID: 84957537145     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S95600     Document Type: Review

References (48)

1. Urabe A. Clinical features of the neutropenic host: definitions and initial evaluation. Clin Infect Dis. 2004;39(Suppl 1):S53–S55
2. Stoppelkamp S, Veseli K, Stang K, Schlensak C, Wendel HP, Walker T. Identification of predictive early biomarkers for Sterile-SIRS after cardiovascular surgery. PLoS One. 2015;10(8):e0135527
3. Dumache R, Rogobete AF, Bedreag OH, et al. Use of miRNAs as biomarkers in sepsis. Anal Cell Pathol (Amst). 2015;2015:186716
4. Liu HH, Guo JB, Geng Y, Su L. Procalcitonin: present and future. Ir J Med Sci. 2015;184(3):597–605
5. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49(Suppl 1):S57–S61
6. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994; 79(6):1605–1608
7. Preas HL, Nylen ES, Snider RH, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001;184(3):373–376
8. Panico C, Nylen E. Procalcitonin beyond the acute phase: novel biomediator properties? BMC Med. 2013;11:189
9. Schefold JC, Bierbrauer J, Weber-Carstens S. Intensive care unitacquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock. J Cachexia Sarcopenia Muscle. 2010;1(2):147–157
10. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518
11. Nakajima A, Yazawa J, Sugiki D, et al. Clinical utility of procalcitonin as a marker of sepsis: a potential predictor of causative pathogens. Intern Med. 2014;53(14):1497–1503
12. Hattori T, Nishiyama H, Kato H, et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. Am J Clin Pathol. 2014;141(1):43–51
13. Charles PE, Ladoire S, Aho S, et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis. 2008;8:38
14. Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection. 2007;35(5):352–355
15. Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med. 2009; 24(4):337–342
16. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10
17. Cornelissen CG, Frechen DA, Schreiner K, Marx N, Kruger S. Inflammatory parameters and prediction of prognosis in infective endocarditis. BMC Infect Dis. 2013;13:272
18. Viallon A, Desseigne N, Marjollet O, et al. Meningitis in adult patients with a negative direct cerebrospinal fluid examination: value of cytochemical markers for differential diagnosis. Crit Care. 2011;15(3):R136
19. Yang SK, Xiao L, Zhang H, et al. Significance of serum procalcitonin as biomarker for detection of bacterial peritonitis: a systematic review and meta-analysis. BMC Infect Dis. 2014;14:452
20. Rao K, Walk ST, Micic D, et al. Procalcitonin levels associate with severity of Clostridium difficile infection. PloS One. 2013;8(3):e58265
21. Cortegiani A, Russotto V, Montalto F, et al. Procalcitonin as a marker of candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol. 2014;14:9
22. Montagna MT, Coretti C, Rella A, et al. The role of procalcitonin in neonatal intensive care unit patients with candidemia. Folia Microbiol. 2013;58(1):27–31
23. Dornbusch HJ, Strenger V, Kerbl R, et al. Procalcitonin – a marker of invasive fungal infection? Support Care Cancer. 2005;13(5):343–346
24. Meisner M, Adina H, Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care. 2006;10(1):R1
25. Kim HS, Yang HT, Hur J, et al. Procalcitonin levels within 48 hours after burn injury as a prognostic factor. Ann Clin Lab Sci. 2012;42(1): 57–64
26. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;24(7):680–684
27. Li Y, Jin ZC, Cai Y, Ji MS, Liu J. Value of serum procalcitonin in evaluating the prognosis of sepsis in elderly patients with colorectal cancer undergoing emergency colorectal surgery. Indian J Surg. 2013;75(2):86–93
28. Picariello C, Lazzeri C, Chiostri M, Gensini GF, Valente S. Kinetic of procalcitonin in patients with cardiogenic shock following acute myocardial infarction: preliminary data. HSR Proc Intensive Care Cardiovasc Anesth. 2010;2(3):201–207
29. Lee WS, Kang DW, Back JH, Kim HL, Chung JH, Shin BC. Cut-off value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients. Korean J Intern Med. 2015; 30(2):198–204
30. Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(9):3034–3042
31. Wang C, Zhong D, Liao Q, Kong L, Liu A, Xiao H. Procalcitonin levels in fresh serum and fresh synovial fluid for the differential diagnosis of knee septic arthritis from rheumatoid arthritis, osteoarthritis and gouty arthritis. Exp Ther Med. 2014;8(4):1075–1080
32. Patout M, Salaun M, Brunel V, Bota S, Cauliez B, Thiberville L. Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47(18):263–267
33. Kaczka K, Mikosinski S, Fendler W, Celnik A, Pomorski L. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Adv Clin Exp Med. 2012;21(2):169–178
34. Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem. 2007;40(5–6):336–342
35. Giovanella L, Suriano S, Ricci R, Ravani P, Ceriani L. Circulating procalcitonin in aseptic carcinoma patients: a specificity study with (18) F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark. Clin Chem Lab Med. 2010;48(8):1163–1165
36. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43(4):468–473
37. Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLoS One. 2015;10(7):e0130999
38. Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer. 2012;118(23):5823–5829
39. Diness LV, Maraldo MV, Mortensen CE, Mellemgaard A, Larsen FO. Procalcitonin and C-reactive protein as markers of bacterial infection in patients with solid tumours. Dan Med J. 2014;61(12):A4984
40. Tulek B, Koylu H, Kanat F, Arslan U, Ozer F. Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients. Contemp Oncol (Pozn). 2013;17(1):68–72
41. Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol. 2014; 21(1):104–106
42. Jimeno A, Garcia-Velasco A, del Val O, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100(11):2462–2469
43. Kim DY, Lee YS, Ahn S, Chun YH, Lim KS. The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat. 2011;43(3):176–180
44. Sandri MT, Passerini R, Leon ME, et al. Procalcitonin as a useful marker of infection in hemato-oncological patients with fever. Anticancer Res. 2008;28(5B):3061–3065
45. Gac AC, Parienti JJ, Chantepie S, et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res. 2011;35(10):1294–1296
46. Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136(4):611–615
47. Niemirowicz K, Swiecicka I, Wilczewska AZ, et al. Growth arrest and rapid capture of select pathogens following magnetic nanoparticle treatment. Colloids Surf B Biointerfaces. 2015;131:29–38
48. Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis. 2013;56(7):943–950.